MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder

Phase 2 Unknown 120 enrolled University of Sydney Monash University · collab Sydney Local Health District · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

To explore the effectiveness of of MDMA-assisted prolonged exposure therapy in improving treatment outcomes for individuals with comorbid PTSD and alcohol use disorder in a double-blind randomised placebo-controlled trial.

Timeline

Start: 2023-09-19
Primary completion: 2026-05
Completion: 2026-05

Publications

Morley KC, Arunogiri S, Mills K, Watt J, Teesson M, Baillie A, Lee YY, Morse A, Back SE, Lubman DI, Haber PS. MDMA-assisted PTSD and Alcohol Therapy Trial (MPATHY): study protocol for a double-blind, randomised, controlled outpatient trial of MDMA-assisted integrated exposure-based therapy for comorbid post-traumatic stress disorder and alcohol use disorder. BMJ Open. 2026 Jul 6;16(7):e114896. doi: 10.1136/bmjopen-2025-114896.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	3,4-methylenedioxymethamphetamine	Unknown	80 mg	—
Subject	3,4-methylenedioxymethamphetamine	Unknown	160 mg	—
Subject	Niacin	Small molecule	250 mg	—

MDMA-assisted Prolonged Exposure Therapy for Comorbid Alcohol Use Disorder and Post-traumatic Stress Disorder

Summary

Timeline

Publications

Drugs

Indications